S
Sera Economics
← US Companies

PEPSICO INC

PEP · Nasdaq · CIK 0000077476

SIC 2080

Beverages

Category

Food & Beverage

Entity

operating

Incorp.

NC

Fiscal Y/E

1226

Source: SEC EDGAR · All filings on SEC →

Investment Indicators

$149.40

-5.22 (-3.38%)

Open

$154.39

High

$154.70

Low

$149.06

Prev Close

$154.62

Volume

5,613,182

52W High

$169.96

52W Low

$122.83

50-day MA

$157.22

Quote as of: 2026-05-11

Market Cap

$213.19B

P/E

24.52

P/B

9.88

PEG

1.66

EPS

6.36

BPS

15.63

Dividend Yield

3.67%

Beta

0.39

ROE

40.38%

ROA

7.67%

D/E Ratio

4.26

Current Ratio

0.85

Gross Margin

54.15%

Operating Margin

12.24%

Net Margin

8.77%

Intrinsic Value Estimates

Multiple valuation methods, each with its own assumptions — outputs can diverge widely

Median consensus (6 methods)

$87.87B

Deep overvalued +142.6%
MethodImplied market capvs current

Graham Number

√(22.5 × 순이익 × 자본)

$61.51B+247%

Graham Formula

순이익 × (8.5 + 2 × 성장률%)

N/A

Justified P/E

순이익 × 산업 평균 P/E

$123.60B+72%

P/B 배수

자본 × 산업 평균 P/B

$30.61B+596%

P/S 배수

매출 × 산업 평균 P/S

$187.85B+13%

DCF (Gordon)

CF × (1+g) / (r − g)

$107.68B+98%

DDM (Gordon)

D × (1+g) / (r − g)

$68.05B+213%
▶ Detailed analysis — formula walk-through & scenarios

Why this conclusion

Of the 7 valuation methods, 6 were applicable. Their median fair-value lands +142.6% below the current market cap → the stock trades above most formulas' estimates (overvalued). 5 methods flag overvalued, 0 flag undervalued, the rest land within fair range. Read each formula's assumptions below before treating any single number as the answer.

Graham Number

Overvalued +246.6%

√(22.5 × 순이익 × 자본)

Current

$213.19B

Implied fair

$61.51B

Gap (current − fair)

+$151.68B(+246.6%)

NetIncome = $8.24B
Equity = $20.41B
√(22.5 × $8.24B × $20.41B) = $61.51B
  • 최대 PER 15배
  • 최대 PBR 1.5배
  • 안정적 흑자 기업 가정 (금융·고성장 부정확)

Graham Formula

순이익 × (8.5 + 2 × 성장률%)

Not applicable: -

Justified P/E

Overvalued +72.5%

순이익 × 산업 평균 P/E

Current

$213.19B

Implied fair

$123.60B

Gap (current − fair)

+$89.59B(+72.5%)

NetIncome = $8.24B
Industry P/E = 15×
$8.24B × 15 = $123.60B
  • 산업 평균 PER 15x 가정 (사용자 정의 가능)
  • 동종 업종 비교가 핵심 — 산업별 평균 P/E 사용 권장

P/B 배수

Overvalued +596.5%

자본 × 산업 평균 P/B

Current

$213.19B

Implied fair

$30.61B

Gap (current − fair)

+$182.58B(+596.5%)

Equity = $20.41B
Industry P/B = 1.5×
$20.41B × 1.5 = $30.61B
  • 산업 평균 PBR 1.5x 가정
  • 은행·보험·자산집약적 산업에 특히 유효

P/S 배수

Fair +13.5%

매출 × 산업 평균 P/S

Current

$213.19B

Implied fair

$187.85B

Gap (current − fair)

+$25.34B(+13.5%)

Revenue = $93.92B
Industry P/S = 2×
$93.92B × 2 = $187.85B
  • 산업 평균 PSR 2x 가정
  • 매출 기반 — 적자 기업·신생 기업에 적용 가능
  • 이익률 차이 무시

DCF (Gordon)

Overvalued +98.0%

CF × (1+g) / (r − g)

Current

$213.19B

Implied fair

$107.68B

Gap (current − fair)

+$105.50B(+98.0%)

FCF = $12.09B
Discount r = 4.0% + 5.0% = 9.0%
Growth g = -2.0%
$12.09B × (1 + -2.0%) / (9.0% − -2.0%) = $107.68B
  • 현금흐름 입력: FCF (잉여현금흐름)
  • 할인율 9.0% (무위험 4.0% + 주식위험프리미엄 5.0%)
  • 영구 성장률 -2.0% (실질 GDP 수준)

DDM (Gordon)

Overvalued +213.3%

D × (1+g) / (r − g)

Current

$213.19B

Implied fair

$68.05B

Gap (current − fair)

+$145.14B(+213.3%)

Dividend D = $7.64B
Discount r = 9.0%
Growth g = -2.0%
$7.64B × (1 + -2.0%) / (9.0% − -2.0%) = $68.05B
  • 배당 입력: 실제 지급 배당
  • 할인율 9.0%
  • 배당 영구 성장률 -2.0%

DCF sensitivity: discount rate × terminal growth

Each cell is the (current vs FCF × (1+g) / (r − g)) discount % under the assumed growth g and discount r.

g \ r7%8%9%10%11%
1%+4.8%+22.2%+39.7%+57.2%+74.6%
2%-13.5%+3.8%+21.0%+38.3%+55.6%
3%-31.5%-14.4%+2.7%+19.9%+37.0%
4%-49.1%-32.2%-15.2%+1.8%+18.7%
5%-66.4%-49.6%-32.8%-16.0%+0.8%

DDM sensitivity: discount rate × dividend growth

Each cell is the discount % vs Dividend × (1+g) / (r − g) under the assumed growth g and discount r.

g \ r7%8%9%10%11%
1%+65.8%+93.4%+121.1%+148.7%+176.4%
2%+36.8%+64.2%+91.5%+118.9%+146.3%
3%+8.4%+35.5%+62.6%+89.7%+116.8%
4%-19.5%+7.4%+34.2%+61.0%+87.9%
5%-46.8%-20.3%+6.3%+32.9%+59.5%

All estimates rest on strong assumptions. Treat the spread, not any single number, as the signal.

Financial Statements

In USD millions (per-share figures shown directly) · Financials as of: 2026-02-03

Income Statement

FY20252024202320222021
Revenue93,92591,85491,47186,39279,474
Cost of Revenue43,06641,74441,88140,57637,075
Gross Profit50,85950,11049,59045,81642,399
Operating Income11,49812,88711,98611,51211,162
Net Income8,2409,5789,0748,9107,618
EPS (Basic)6.026.976.596.455.51
EPS (Diluted)6.006.956.566.425.49

Balance Sheet

FY20252024202320222021
Total Assets107,39999,467100,49592,18792,377
Current Assets27,94925,82626,95021,53921,783
Cash & Equivalents9,1598,5059,7114,9545,596
Total Liabilities86,85281,29681,85874,91476,226
Current Liabilities32,76431,53631,64726,78526,220
Long-term Debt46,35141,22841,51938,75339,898
Total Equity20,40618,04118,50317,14916,043

Cash Flow

FY20252024202320222021
Operating CF12,08712,50713,44210,81111,616
Investing CF-6,879-5,472-5,495-2,430-3,269
Financing CF-4,979-7,556-3,009-8,523-10,780
Dividends Paid7,6387,2296,6826,1725,815

📄 SEC Filings

Other filings (80)
4

Insider Transaction

FORM 4

2026-05-08

Open →

3

3

FORM 3

2026-05-08

Open →

SCHEDULE 13G

SCHEDULE 13G

xslSCHEDULE_13G_X02/primary_doc.xml

2026-04-29

Open →

PX14A6G

PX14A6G

o428261px14a6g.htm

2026-04-28

Open →

25-NSE

25-NSE

xslF25X02/primary_doc.xml

2026-04-27

Open →

PX14A6G

PX14A6G

o472612px14a6g.htm

2026-04-08

Open →

PX14A6G

PX14A6G

o472612px14a6g.htm

2026-04-07

Open →

PX14A6G

PX14A6G

z41261px14a6g.htm

2026-04-01

Open →

ARS

ARS

ANNUAL REPORT TO SECURITY HOLDERS

2026-03-27

Open →

DEFA14A

DEFA14A

DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS

2026-03-27

Open →

SCHEDULE 13G/A

SCHEDULE 13G/A

xslSCHEDULE_13G_X02/primary_doc.xml

2026-03-27

Open →

4

Insider Transaction

FORM 4

2026-03-06

Open →

144

144

xsl144X01/primary_doc.xml

2026-03-04

Open →

144

144

xsl144X01/primary_doc.xml

2026-03-04

Open →

4

Insider Transaction

FORM 4

2026-03-04

Open →

4

Insider Transaction

FORM 4

2026-03-03

Open →

4

Insider Transaction

FORM 4

2026-03-03

Open →

4

Insider Transaction

FORM 4

2026-03-03

Open →

4

Insider Transaction

FORM 4

2026-03-03

Open →

4

Insider Transaction

FORM 4

2026-03-03

Open →

4

Insider Transaction

FORM 4

2026-03-03

Open →

4

Insider Transaction

FORM 4

2026-03-03

Open →

4

Insider Transaction

FORM 4

2026-03-03

Open →

4

Insider Transaction

FORM 4

2026-03-03

Open →

144

144

xsl144X01/primary_doc.xml

2026-03-02

Open →

144

144

xsl144X01/primary_doc.xml

2026-03-02

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-25

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-23

Open →

CERT

CERT

PEP CERTIFICATION - BONDS

2026-02-12

Open →

8-A12B

8-A12B

FORM 8-A12B

2026-02-12

Open →

424B2

424B2

424B2

2026-02-05

Open →

FWP

FWP

FWP

2026-02-05

Open →

424B2

424B2

424B2

2026-02-04

Open →

3

3

FORM 3

2026-01-07

Open →

4

Insider Transaction

FORM 4

2025-12-03

Open →

4

Insider Transaction

FORM 4

2025-12-03

Open →

4

Insider Transaction

FORM 4

2025-12-03

Open →

4

Insider Transaction

FORM 4

2025-12-03

Open →

4

Insider Transaction

FORM 4

2025-12-03

Open →

4

Insider Transaction

FORM 4

2025-11-12

Open →

3

3

FORM 3

2025-11-12

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

4

Insider Transaction

FORM 4

2025-10-03

Open →

3/A

3/A

FORM 3/A

2025-08-08

Open →

CERT

CERT

CERT

2025-07-29

Open →

8-A12B

8-A12B

8-A12B

2025-07-28

Open →

424B2

424B2

424B2

2025-07-22

Open →

424B2

424B2

424B2

2025-07-22

Open →

FWP

FWP

FWP

2025-07-22

Open →

FWP

FWP

FWP

2025-07-21

Open →

424B2

424B2

424B2

2025-07-21

Open →

424B2

424B2

424B2

2025-07-21

Open →

4

Insider Transaction

FORM 4

2025-07-03

Open →

11-K

11-K

11-K

2025-06-13

Open →

SCHEDULE 13G/A

SCHEDULE 13G/A

xslSCHEDULE_13G_X01/primary_doc.xml

2025-06-05

Open →

4

Insider Transaction

FORM 4

2025-06-03

Open →

4

Insider Transaction

FORM 4

2025-06-03

Open →

4

Insider Transaction

FORM 4

2025-06-03

Open →

4

Insider Transaction

FORM 4

2025-06-03

Open →

4

Insider Transaction

FORM 4

2025-06-03

Open →

4

Insider Transaction

FORM 4

2025-06-03

Open →

SD

SD

SD

2025-05-30

Open →

3

3

FORM 3

2025-05-09

Open →

PX14A6G

PX14A6G

BOWYER RESEARCH - PX14A6G

2025-05-06

Open →

PX14A6G

PX14A6G

e417250px14a6g.htm

2025-04-18

Open →

PX14A6G

PX14A6G

o49252px14a6g.htm

2025-04-09

Open →

PX14A6G

PX14A6G

w41253px14a6g.htm

2025-04-01

Open →

ARS

ARS

ANNUAL REPORT TO SECURITY HOLDERS

2025-03-28

Open →